Literature DB >> 19060872

Cancer and complement.

Suzanne Ostrand-Rosenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19060872      PMCID： PMC2800820          DOI： 10.1038/nbt1208-1348

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  12 in total

1.  Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.

Authors:  Stephanie K Bunt; Pratima Sinha; Virginia K Clements; Jeff Leips; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

2.  Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.

Authors:  Pratima Sinha; Chinonyerem Okoro; Dirk Foell; Hudson H Freeze; Suzanne Ostrand-Rosenberg; Geetha Srikrishna
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells.

Authors:  Xiaoping Song; Yakov Krelin; Tatyana Dvorkin; Olle Bjorkdahl; Shraga Segal; Charles A Dinarello; Elena Voronov; Ron N Apte
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 4.  Immune evasion of tumor cells using membrane-bound complement regulatory proteins.

Authors:  A Gorter; S Meri
Journal:  Immunol Today       Date:  1999-12

5.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.

Authors:  Li Yang; Laura M DeBusk; Koari Fukuda; Barbara Fingleton; Brenda Green-Jarvis; Yu Shyr; Lynn M Matrisian; David P Carbone; P Charles Lin
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

6.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

Authors:  D I Gabrilovich; H L Chen; K R Girgis; H T Cunningham; G M Meny; S Nadaf; D Kavanaugh; D P Carbone
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

7.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.

Authors:  Cecilia Melani; Claudia Chiodoni; Guido Forni; Mario P Colombo
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

8.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.

Authors:  Paulo C Rodriguez; Claudia P Hernandez; David Quiceno; Steven M Dubinett; Jovanny Zabaleta; Juan B Ochoa; Jill Gilbert; Augusto C Ochoa
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

9.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.

Authors:  Pingyan Cheng; Cesar A Corzo; Noreen Luetteke; Bin Yu; Srinivas Nagaraj; Marylin M Bui; Myrna Ortiz; Wolfgang Nacken; Clemens Sorg; Thomas Vogl; Johannes Roth; Dmitry I Gabrilovich
Journal:  J Exp Med       Date:  2008-09-22       Impact factor: 14.307

10.  Modulation of the antitumor immune response by complement.

Authors:  Maciej M Markiewski; Robert A DeAngelis; Fabian Benencia; Salome K Ricklin-Lichtsteiner; Anna Koutoulaki; Craig Gerard; George Coukos; John D Lambris
Journal:  Nat Immunol       Date:  2008-09-28       Impact factor: 25.606
View more
  27 in total

1.  Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population.

Authors:  Yingwen Liu; Yanghui Bi; Jia Lin; Lei Cao; Bing He; Zhi Zhang; Yongping Cui; Xuemei Zhang
Journal:  Tumour Biol       Date:  2014-11-15

Review 2.  Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Trends Immunol       Date:  2009-05-08       Impact factor: 16.687

Review 3.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 4.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

5.  S100A8/A9 activate key genes and pathways in colon tumor progression.

Authors:  Mie Ichikawa; Roy Williams; Ling Wang; Thomas Vogl; Geetha Srikrishna
Journal:  Mol Cancer Res       Date:  2011-01-12       Impact factor: 5.852

Review 6.  Immunological effects and therapeutic role of C5a in cancer.

Authors:  Victoria R Darling; Ralph J Hauke; Stefano Tarantolo; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-12       Impact factor: 4.473

7.  Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.

Authors:  Chunmei Piao; Lun Cai; Shulan Qiu; Lixin Jia; Wenchao Song; Jie Du
Journal:  J Biol Chem       Date:  2015-03-04       Impact factor: 5.157

8.  Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.

Authors:  Lacey Gunn; Chuanlin Ding; Min Liu; Yunfeng Ma; Chunjian Qi; Yihua Cai; Xiaoling Hu; Deep Aggarwal; Huang-Ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2012-08-22       Impact factor: 5.422

Review 9.  Unwelcome complement.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 10.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.